- Home
- MDXH vs INMB Comparison
MDXH vs INMB Comparison
Compare MDXH & INMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MDXH | INMB |
|---|---|---|
| Founded | 2003 | 2015 |
| Country | Belgium | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 41.1M | 37.2M |
| IPO Year | 2021 | 2018 |
Fundamental Metrics
Financial Performance| Metric | MDXH | INMB |
|---|---|---|
| Price | $0.76 | $1.42 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 5 |
| Target Price | ★ $7.67 | $5.40 |
| AVG Volume (30 Days) | ★ 989.2K | 421.4K |
| Earning Date | 05-14-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 11.85 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $50,000.00 |
| Revenue This Year | $30.78 | N/A |
| Revenue Next Year | $18.31 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 257.14 |
| 52 Week Low | $0.68 | $1.09 |
| 52 Week High | $5.33 | $11.64 |
Technical Indicators
Market Signals| Indicator | MDXH | INMB |
|---|---|---|
| Relative Strength Index (RSI) | 14.92 | 48.57 |
| Support Level | $0.68 | $1.37 |
| Resistance Level | $2.30 | $1.51 |
| Average True Range (ATR) | 0.11 | 0.11 |
| MACD | -0.03 | -0.01 |
| Stochastic Oscillator | 5.32 | 20.83 |
Price Performance
Historical ComparisonAbout MDXH MDxHealth SA
MDxHealth SA is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. Its tests are based on proprietary genomic, epigenetic, and other molecular technologies and assist physicians with the diagnosis of urologic cancers, the prognosis of recurrence risk, and the prediction of response to a specific therapy. It derives revenues from clinical laboratory service testing or the out-licensing of the company's patented DNA methylation platform and biomarkers. Geographically, it derives revenue from the United States of America (USA) and Europe.
About INMB INmune Bio Inc.
INmune Bio Inc is a clinical stage biotechnology pharmaceutical company focused on developing and commercializing its product candidates to treat diseases where inflammation and immunology cause a dysfunctional immune system contributing to disease. The company's pipeline products include INKmune, XPro1595, and others. It has three product platforms; The CORDStrom product platform, The DN-TNF product platform, and The Natural Killer Cell Priming Platform.